BUFFALO, N.Y., June 28, 2016 /PRNewswire/ -- OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive(SM) panel, a 144 gene, pan-cancer, next-generation sequencing (NGS) tumor profiling diagnostic panel to guide oncology treatment decision-making. OmniSeq Comprehensive provides access to more than 650 therapeutic associations and 850 clinical trial associations, and identifies contraindications for drugs not appropriate for a particular patient.
"OmniSeq is proud to receive New York State CLEP approval for OmniSeq Comprehensive. CLEP is the highest standard of Clinical Laboratory Improvement Amendments (CLIA) laboratory validation," said Carl Morrison, MD, DVM, President and Chief Scientific Officer of OmniSeq and Executive Director of the Roswell Park Center for Personalized Medicine. "OmniSeq Comprehensive's small sample requirements – as little as one tenth of the typical sample requirement, amongst the least in the industry – will enable us to generate complete results from a high proportion of precious samples. This panel enables physicians to zero in on the most important results for patient outcomes."
According to a November, 2015 article in the Journal of Clinical Oncology (Schwaederle et. al), patients who received targeted therapy in a personalized way based on harboring a molecular biomarker demonstrated significantly better response and survival rates. OmniSeq Comprehensive was developed using Thermo Fisher Scientific's Oncomine reagents and the Ion Torrent sequencing system, which are also being used by the National Cancer Institute's (NCI) MATCH trial (NCT02465060) - the largest precision medicine clinical trial of its kind. Thus, OmniSeq Comprehensive improves patient access to targeted therapeutic options available in clinical trials.
As part of OmniSeq's mission to advance precision medicine, OmniSeq is also proud to announce it is partnering with Cure Forward to help patients control their care and be recruited for clinical trials through its Clinical Trial Exchange. Patients can obtain their OmniSeq Comprehensive test results online and directly apply that information to understand their disease and treatment options. On Cure Forward's platform, trial sponsors can identify patients who match their selection criteria and invite them to apply to their studies.
"Patients and their families are becoming increasingly active participants in devising strategies for their care. Precision medicine is a framework for matching patients to the particular therapies that match their condition," said Martin Naley, Founder, Chief Strategy Officer of Cure Forward.
"Cure Forward offers a unique platform that proactively connects patients to clinical trials, which fits perfectly into our mission as we offer patients more than just therapeutically actionable molecular diagnostic testing, but a complete service experience," said Mark Gardner, Chief Executive Officer of OmniSeq. "Our vision is find the right drug or the right clinical trial for every patient, and our partnership with Cure Forward helps OmniSeq fulfill our promise to patients and providers to deliver the best therapeutic support possible."
OmniSeq, LLC was created from the Center for Personalized Medicine at Roswell Park Cancer Institute. OmniSeq is a CLIA certified and NYS CLEP approved molecular laboratory that is committed to improving access to the most informative molecular tumor profiling insights to help guide comprehensive cancer care. OmniSeq addresses the complete customer experience through their OmniSeq CARES(SM) Service Program which focuses on both the physician and patient by facilitating everything from sample retrieval and clinical report consultation, to insurance navigation, financial assistance and clinical trial access. Headquartered in Buffalo, NY, OmniSeq offers services throughout the U.S. For more information, call 1-800-781-1259 or visit www.omniseq.com.
Director of Marketing
Office: (716) 898-8582
About Cure Forward
Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company's platform is in beta release at www.cureforward.com.
Coltrin & Associates
Jennifer Webb, 212-221-1616
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omniseq-receives-new-york-clep-approval-for-144-gene-comprehensive-panel-and-partners-with-cure-forward-to-advance-precision-medicine-for-cancer-patients-300291467.html
SOURCE OmniSeq, LLC